Attorney General Mike Hilgers Urges Consumers to Claim Compensation for Inflated Generic Drug Prices

Lincoln – Attorney General Hilger is urging consumers to check their eligibility for compensation for certain generic drug purchases and to submit a claim for compensation here. This month, the U.S. District Court for the District of Connecticut granted preliminary approval of a plan, filed by Nebraska and a coalition of 47 other states and territories, to distribute settlement funds paid by generic drug manufacturers in exchange for settlement of claims that those companies illegally conspired to raise the prices of generic drugs.

Lincoln – Attorney General Hilger is urging consumers to check their eligibility for compensation for certain generic drug purchases and to submit a claim for compensation here. This month, the U.S. District Court for the District of Connecticut granted preliminary approval of a plan, filed by Nebraska and a coalition of 47 other states and territories, to distribute settlement funds paid by generic drug manufacturers in exchange for settlement of claims that those companies illegally conspired to raise the prices of generic drugs. The coalition previously announced settlements with the manufacturers Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure, totaling approximately $96.5 million. The multistate coalition’s distribution plan aims to return millions of dollars from those settlement funds to those potentially harmed by the elevated prices of the generic drugs that are the subjects of those settlements. If you purchased a generic drug listed here between May 2009 and December 2019, you may be eligible for compensation. To determine your eligibility, call 1-866-290-0182 (Toll-Free), email [email protected] or visit www.AGGenericDrugs.com. Nebraska and nearly all other states and territories engaged in a series of antitrust cases against major generic drug manufacturers, beginning in 2016. These cases involve dozens of companies and individuals accused of price-fixing and fraudulent conduct related to generic drugs. Seven pharmaceutical executives are cooperating with the States. The above-mentioned cases stem from a series of investigations built on evidence from several cooperating witnesses at the core of the different conspiracies, millions of documents, and a massive phone record data base. Each complaint addresses a different set of drugs and defendants and lays out an interconnected web of competing industry executives who regularly met and communicated with each other, providing ample opportunity to form illegal agreements. The complaints note that defendants used terms like "fair share," "playing nice in the sandbox," and "responsible competitor" to unlawfully discourage competition, raise prices, and enforce an ingrained culture of collusion. Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming joined in today’s announcement.